imipramine has been researched along with Memory Disorders in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (25.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (18.75) | 29.6817 |
| 2010's | 6 (37.50) | 24.3611 |
| 2020's | 3 (18.75) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, P; Leng, C; Li, X; Liu, W; Ma, Q; Pan, W; Sang, Z; Tan, Z; Wang, K; Xu, Q; Yang, Y; Yu, L | 1 |
| Bai, P; Cheng, X; Cheng, Y; Lu, X; Sang, Z; Shi, J; Wang, K; Yang, J; Zhang, P; Zhang, Q; Zheng, C | 1 |
| Brinza, I; El-Kashak, W; Eldahshan, OA; Hritcu, L; Raey, MAE | 1 |
| Bobula, B; Stachowicz, K; Tokarski, K | 1 |
| Ahmadiani, A; Askari, S; Dargahi, L; Ghasemi, R; Javadpour, P; Rashidi, FS | 1 |
| Comim, CM; de Rezende, VB; Jeromin, A; Magno, LA; Quevedo, J; Rodrigues, AL; Romano-Silva, MA; Rosa, DV; Vidigal, P | 1 |
| Gawel, K; Gibula-Bruzda, E; Jenda, M; Kotlinska, JH; Marszalek-Grabska, M | 1 |
| Barish, PA; Li, G; Li, S; Lin, D; Ogle, WO; Pan, J; Shyamala, SG; Vernon, MM; Xu, Y | 1 |
| Chavant, F; Deguil, J; Fauconneau, B; Ingrand, I; Lafay-Chebassier, C; Milin, S; Pain, S; Pérault-Pochat, MC | 1 |
| Cespuglio, R; Cline, BH; Malin, D; Pavlova, GV; Revishchin, AV; Steinbusch, HW; Strekalova, T | 1 |
| Blanco, C; Garcia-Toro, M; Gonzalez, A; Gonzalez, E; Saiz-Ruiz, J; Talavera, JA; Tejada, P | 1 |
| Azarmina, P; Rostami, P; Shafaghi, B; Shamsi, T; Zarrindast, MR | 1 |
| Crowe, RR | 1 |
| Fischman, MW; Glass, RM; Hartel, FW; Matuzas, W; Uhlenhuth, EH | 1 |
| Jarvik, ME; Sternberg, DE | 1 |
| Groh, RH; Jenkins, RB | 1 |
1 review(s) available for imipramine and Memory Disorders
| Article | Year |
|---|---|
Current concepts. Electroconvulsive therapy--a current perspective.
Topics: Depression; Electroconvulsive Therapy; Humans; Imipramine; Memory Disorders; Methods; Patient Acceptance of Health Care; Schizophrenia | 1984 |
1 trial(s) available for imipramine and Memory Disorders
| Article | Year |
|---|---|
Cognitive dysfunction and imipramine in outpatient depressive.
Topics: Adult; Attention; Clinical Trials as Topic; Cognition Disorders; Depressive Disorder; Double-Blind Method; Female; Humans; Imipramine; Male; Memory Disorders; Middle Aged; Psychomotor Disorders; Random Allocation | 1981 |
14 other study(ies) available for imipramine and Memory Disorders
| Article | Year |
|---|---|
Design, synthesis and evaluation of novel ferulic acid-O-alkylamine derivatives as potential multifunctional agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Blood-Brain Barrier; Butyrylcholinesterase; Cholinesterase Inhibitors; Coumaric Acids; Drug Design; Eels; Humans; Memory Disorders; Mice; PC12 Cells; Rats | 2017 |
Development of chalcone-O-alkylamine derivatives as multifunctional agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Biological Transport; Blood-Brain Barrier; Butyrylcholinesterase; Chalcones; Chelating Agents; Cholinesterase Inhibitors; Coordination Complexes; Copper; Drug Design; Female; Humans; Male; Memory Disorders; Mice; Molecular Docking Simulation; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Protein Binding; Scopolamine; Structure-Activity Relationship | 2019 |
Sweroside Ameliorated Memory Deficits in Scopolamine-Induced Zebrafish (
Topics: Acetylcholinesterase; Animals; Anti-Bacterial Agents; Antifungal Agents; Antioxidants; Brain; Cholinergic Agents; Galantamine; Glucose; Hypnotics and Sedatives; Imipramine; Iridoid Glucosides; Maze Learning; Memory Disorders; Oxidative Stress; Scopolamine; Sugars; Zebrafish | 2022 |
NS398, a cyclooxygenase-2 inhibitor, reverses memory performance disrupted by imipramine in C57Bl/6J mice.
Topics: Animals; Antidepressive Agents, Tricyclic; Brain; Cyclooxygenase 2 Inhibitors; Imipramine; Maze Learning; Memory; Memory Disorders; Mice; Mice, Inbred C57BL; Nitrobenzenes; Organ Culture Techniques; Sulfonamides | 2020 |
Imipramine alleviates memory impairment and hippocampal apoptosis in STZ-induced sporadic Alzheimer's rat model: Possible contribution of MAPKs and insulin signaling.
Topics: Adrenergic Uptake Inhibitors; Alzheimer Disease; Animals; Antibiotics, Antineoplastic; Behavior, Animal; Disease Models, Animal; Hippocampus; Imipramine; Insulin; Male; MAP Kinase Signaling System; Memory Disorders; Rats; Rats, Wistar; Streptozocin | 2021 |
NCS-1 deficiency causes anxiety and depressive-like behavior with impaired non-aversive memory in mice.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Anxiety Disorders; Avoidance Learning; Depressive Disorder; Diazepam; Exploratory Behavior; Imipramine; Male; Memory Disorders; Memory, Long-Term; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Neuronal Calcium-Sensor Proteins; Neuropeptides; Recognition, Psychology; Social Behavior | 2014 |
Memantine improves memory impairment and depressive-like behavior induced by amphetamine withdrawal in rats.
Topics: Amphetamine; Amphetamine-Related Disorders; Animals; Antidepressive Agents; Central Nervous System Stimulants; Depression; Disease Models, Animal; Dizocilpine Maleate; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Imipramine; Male; Memantine; Memory Disorders; Muscarinic Antagonists; Nootropic Agents; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Recognition, Psychology; Scopolamine; Substance Withdrawal Syndrome | 2016 |
Curcumin reverses impaired cognition and neuronal plasticity induced by chronic stress.
Topics: Animals; Antidepressive Agents, Tricyclic; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Cells, Cultured; Cognition Disorders; Corticosterone; Curcumin; Hippocampus; Imipramine; Learning Disabilities; Male; Maze Learning; Memory Disorders; Neuronal Plasticity; Neuroprotective Agents; Pyramidal Cells; Random Allocation; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Space Perception; Stress, Psychological | 2009 |
Imipramine, in part through tumor necrosis factor alpha inhibition, prevents cognitive decline and beta-amyloid accumulation in a mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Cognition; Disease Models, Animal; Frontal Lobe; Hippocampus; Imipramine; Injections, Intraventricular; Male; Memory; Memory Disorders; Mice; Neuroprotective Agents; Peptide Fragments; Tumor Necrosis Factor-alpha | 2010 |
The neuronal insulin sensitizer dicholine succinate reduces stress-induced depressive traits and memory deficit: possible role of insulin-like growth factor 2.
Topics: Animals; Antidepressive Agents; Anxiety; Depression; Disease Models, Animal; Hippocampus; Imipramine; Insulin-Like Growth Factor II; Male; Memory Disorders; Mice; Mice, Inbred ICR; Neurons; Receptor, Insulin; Stress, Psychological; Succinylcholine; Up-Regulation | 2012 |
Audioverbal cognitive dysfunction in depression. Factors involved.
Topics: Adolescent; Adult; Antidepressive Agents; Antidepressive Agents, Tricyclic; Attention; Cognition Disorders; Depression; Female; Humans; Imipramine; Male; Memory Disorders; Middle Aged; Reaction Time; Sertraline; Severity of Illness Index; Task Performance and Analysis | 2003 |
GABAergic system and imipramine-induced impairment of memory retention in rats.
Topics: Animals; Avoidance Learning; Dose-Response Relationship, Drug; GABA Agonists; GABA Antagonists; GABA-B Receptor Agonists; GABA-B Receptor Antagonists; gamma-Aminobutyric Acid; Imipramine; Male; Memory Disorders; Rats; Rats, Wistar; Receptors, GABA-B; Retention, Psychology | 2004 |
Memory functions in depression.
Topics: Amitriptyline; Depression; Female; Humans; Imipramine; Male; Memory Disorders; Memory, Short-Term | 1976 |
Mental symptoms in Parkinsonian patients treated with L-dopa.
Topics: Aged; Behavior; Depression; Dihydroxyphenylalanine; Dreams; Female; Humans; Imipramine; Male; Memory Disorders; Mental Disorders; Middle Aged; Parkinson Disease; Psychoses, Substance-Induced; Sleep | 1970 |